PTE News and Press, PolarityTE Inc. From 11/09/21

ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...

PolarityTE to Report Third Quarter Financial Results on November 10, 2021 PR Newswire SALT LAKE CITY , Oct. 28, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) today announced that it will report results for the quarter ended September 30, 2021 ...

PolarityTE Provides Update on Investigational New Drug Application PR Newswire SALT LAKE CITY , Oct. 7, 2021 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided an...

PolarityTE, Inc. (Nasdaq: PTE) a biotechnology company developing regenerative tissue products and biomaterials, announced today that it will present at the H.C. Wainwright 23 rd Annual Global Investment Conference on September 13, 2021 and participate in a fireside chat at the ...

Ryan Mathis, MD, named Chief Medical Officer PolarityTE, Inc. (Nasdaq: PTE) today announced the appointment of Richard Hague as Chief Executive Officer, the election of David Seaburg to the Board of Directors, and the appointment of Ryan Mathis, MD, as Chief Medical Offi...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips BioPath (NASDAQ: BPTH ) stock is soaring higher on Tuesday after revealing an update on its Investigational New Drug (IND) application for BP1002. Source: CI Photos / Shutterstock.com The U.S. Food and Drug Ad...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips PolarityTE (NASDAQ: PTE ) stock is taking a beating on Tuesday after the biotechnology company got an update from the U.S. Food and Drug Administration (FDA) on its Investigational New Drug Application (IND). Sour...

PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing regenerative tissue products and biomaterials, today provided an update regarding correspondence from the U.S. Food and Drug Administration (FDA) related to its Investigational New Drug Application (IND) for SkinTE ...

PolarityTE, Inc. (PTE) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Rich Haerle – Vice President-Investor Relations David Seaburg – Chief Executive Officer Richard Hague – President and Chief Operating Officer Jake Patterson – In...

PolarityTE to host conference call and webcast today, August 12, 2021, at 4:30 p.m. ET PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for th...